C. Boyce

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir and Emtricitabine plus Twice-Daily Nevirapine

R. Redfield, R. Talwani, B. Gilliam, 2009, HIV clinical trials.

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.

K. Neuzil, Wilbur H. Chen, R. Borrow, 2018, The Lancet. Infectious diseases.

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.

Zonghui Hu, A. McDermott, J. Gall, 2023, The Lancet. Infectious diseases.